Aberrant activation of the epidermal growth factor receptor (EGFR/ERBB1) by erythroblastic
leukemia viral oncogene homolog (ERBB) ligands contributes to various tumor …

Although clinical management of colon cancer generally has not accounted for the primary
tumor site, left-sided and right-sided colon cancers harbor different clinical and biologic …

Metastatic colorectal cancers (mCRCs) are clinically heterogeneous, but the genomic basis
of this variability remains poorly understood. We performed prospective targeted sequencing …

PURPOSE CALGB/SWOG 80405 was a randomized phase III trial that found no statistically
significant difference in overall survival (OS) in patients with first-line metastatic colorectal …

Metastatic colorectal carcinoma (mCRC) is a heterogeneous disease with differing
outcomes and clinical responses and poor prognosis. CRCs can be characterised by their …

The consensus molecular subtypes (CMS) classification is one of the most robust colorectal
cancer (CRC) classifications based on comprehensive gene expression profiles. This study …

BRAF-mutated advanced colorectal cancer is a relatively small but critical subset of this
tumor type on the basis of prognostic and predictive implications. BRAF alterations in …

Cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth
factor receptor (EGFR), have clinical activity in the patients with metastatic colorectal cancer …

Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the
treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most …

Colorectal cancer (CRC), one of the leading causes of death among cancer patients, is a
heterogeneous disease and is characterized by diversions in multiple molecular pathways …